优化抗CD70 CAR T细胞靶向高危多发性骨髓瘤基因型
尽管靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)T细胞在多发性骨髓瘤中取得成功,高危细胞遗传学特征患者仍最快复发,亟需额外治疗选择。本研究识别CD70为高危骨髓瘤肿瘤中特异性上调的细胞表面抗原,通过结构指导设计出基于CD27的抗CD70 CAR-T,其体内扩增优于所有测试的单链可变片段CAR,并预测驱动CD70上调的关键转录因子及双靶向策略以避免抗原逃逸。
要点
- CD70在高危细胞遗传学特征的多发性骨髓瘤中特异性上调。
- 基于CD27的抗CD70 CAR-T在体内扩增优于所有测试的单链可变片段CAR。
- 双靶向CD70或BCMA的CAR-T可能避免抗原逃逸介导的耐药。
核心结论
- 靶向CD70的优化CAR-T在多发性骨髓瘤中具有前景,并支持该方法的未来临床转化。
研究设计与样本
- 研究通过结构指导设计定义基于CD27的抗CD70 CAR-T,并与所有测试的单链可变片段CAR进行比较;采用机器学习进行表观遗传分析预测驱动CD70上调的关键转录因子和转录网络。
主要发现
- CD70被识别为高危骨髓瘤肿瘤中特异性上调的细胞表面抗原。
- 基于CD27的抗CD70 CAR-T在体内扩增优于所有测试的单链可变片段CAR,改善超过80倍。
- 机器学习表观遗传分析预测了驱动高危骨髓瘤中CD70上调的关键转录因子和转录网络。
- 针对CD70或BCMA的双靶向CAR-T展示了一种避免抗原逃逸介导耐药的潜在策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the success of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells (CAR-Ts) in multiple myeloma, patients with high-risk cytogenetic features continue to relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested single-chain variable fragment-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.
引用
- Kasap C, Izgutdina A, Patiño-Escobar B, et al. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells. Blood. 2025. PMID: 40359480. doi:10.1182/blood.2024025536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。